• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非人类灵长类动物中的 SARS-CoV-2 病毒动力学。

SARS-CoV-2 viral dynamics in non-human primates.

机构信息

Université de Paris, IAME, INSERM, Paris, France.

Université Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT), Fontenay-aux-Roses & Le Kremlin-Bicêtre, France.

出版信息

PLoS Comput Biol. 2021 Mar 17;17(3):e1008785. doi: 10.1371/journal.pcbi.1008785. eCollection 2021 Mar.

DOI:10.1371/journal.pcbi.1008785
PMID:33730053
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8007039/
Abstract

Non-human primates infected with SARS-CoV-2 exhibit mild clinical signs. Here we used a mathematical model to characterize in detail the viral dynamics in 31 cynomolgus macaques for which nasopharyngeal and tracheal viral load were frequently assessed. We identified that infected cells had a large burst size (>104 virus) and a within-host reproductive basic number of approximately 6 and 4 in nasopharyngeal and tracheal compartment, respectively. After peak viral load, infected cells were rapidly lost with a half-life of 9 hours, with no significant association between cytokine elevation and clearance, leading to a median time to viral clearance of 10 days, consistent with observations in mild human infections. Given these parameter estimates, we predict that a prophylactic treatment blocking 90% of viral production or viral infection could prevent viral growth. In conclusion, our results provide estimates of SARS-CoV-2 viral kinetic parameters in an experimental model of mild infection and they provide means to assess the efficacy of future antiviral treatments.

摘要

非人类灵长类动物感染 SARS-CoV-2 后会出现轻微的临床症状。在这里,我们使用数学模型详细描述了 31 只猕猴的病毒动力学特征,这些猕猴的鼻咽和气管病毒载量经常被评估。我们发现感染细胞的爆发量很大(>104 病毒),鼻咽和气管腔室中的宿主内繁殖基本数分别约为 6 和 4。在病毒载量达到峰值后,感染细胞迅速丢失,半衰期为 9 小时,细胞因子升高与清除之间没有显著关联,导致病毒清除的中位时间为 10 天,与轻度人类感染的观察结果一致。鉴于这些参数估计,我们预测阻断 90%病毒产生或病毒感染的预防性治疗可以防止病毒生长。总之,我们的研究结果提供了轻度感染实验模型中 SARS-CoV-2 病毒动力学参数的估计值,并为评估未来抗病毒治疗的疗效提供了手段。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2df5/8007039/42000f81b2de/pcbi.1008785.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2df5/8007039/b428179477ef/pcbi.1008785.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2df5/8007039/f64c92a0b918/pcbi.1008785.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2df5/8007039/ebd95a21a6aa/pcbi.1008785.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2df5/8007039/254ffd4f6713/pcbi.1008785.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2df5/8007039/671f2440b744/pcbi.1008785.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2df5/8007039/42000f81b2de/pcbi.1008785.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2df5/8007039/b428179477ef/pcbi.1008785.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2df5/8007039/f64c92a0b918/pcbi.1008785.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2df5/8007039/ebd95a21a6aa/pcbi.1008785.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2df5/8007039/254ffd4f6713/pcbi.1008785.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2df5/8007039/671f2440b744/pcbi.1008785.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2df5/8007039/42000f81b2de/pcbi.1008785.g006.jpg

相似文献

1
SARS-CoV-2 viral dynamics in non-human primates.非人类灵长类动物中的 SARS-CoV-2 病毒动力学。
PLoS Comput Biol. 2021 Mar 17;17(3):e1008785. doi: 10.1371/journal.pcbi.1008785. eCollection 2021 Mar.
2
Modeling Within-Host Dynamics of SARS-CoV-2 Infection: A Case Study in Ferrets.建模 SARS-CoV-2 感染的宿主内动力学:以雪貂为例的案例研究。
Viruses. 2021 Aug 18;13(8):1635. doi: 10.3390/v13081635.
3
Success of prophylactic antiviral therapy for SARS-CoV-2: Predicted critical efficacies and impact of different drug-specific mechanisms of action.预防性抗 SARS-CoV-2 病毒治疗的成功:预测的临界疗效和不同药物特异性作用机制的影响。
PLoS Comput Biol. 2021 Mar 1;17(3):e1008752. doi: 10.1371/journal.pcbi.1008752. eCollection 2021 Mar.
4
Incomplete antiviral treatment may induce longer durations of viral shedding during SARS-CoV-2 infection.不完整的抗病毒治疗可能会导致 SARS-CoV-2 感染期间病毒脱落时间延长。
Life Sci Alliance. 2021 Aug 3;4(10). doi: 10.26508/lsa.202101049. Print 2021 Oct.
5
Subacute SARS-CoV-2 replication can be controlled in the absence of CD8+ T cells in cynomolgus macaques.在食蟹猴中,即使没有 CD8+ T 细胞,也可以控制亚急性 SARS-CoV-2 复制。
PLoS Pathog. 2021 Jul 19;17(7):e1009668. doi: 10.1371/journal.ppat.1009668. eCollection 2021 Jul.
6
Efficacy of late-onset antiviral treatment in immunocompromised hosts with persistent SARS-CoV-2 infection.免疫功能低下宿主持续性 SARS-CoV-2 感染的晚期抗病毒治疗效果。
J Virol. 2024 Sep 17;98(9):e0090524. doi: 10.1128/jvi.00905-24. Epub 2024 Aug 29.
7
Protective Effects of Astodrimer Sodium 1% Nasal Spray Formulation against SARS-CoV-2 Nasal Challenge in K18-hACE2 Mice.1%阿斯托地瑞钠鼻喷雾剂对K18-hACE2小鼠SARS-CoV-2鼻腔攻击的保护作用
Viruses. 2021 Aug 20;13(8):1656. doi: 10.3390/v13081656.
8
Neutralizing antibody-dependent and -independent immune responses against SARS-CoV-2 in cynomolgus macaques.食蟹猴中针对 SARS-CoV-2 的中和抗体依赖和非依赖免疫应答。
Virology. 2021 Feb;554:97-105. doi: 10.1016/j.virol.2020.12.013. Epub 2020 Dec 29.
9
The Post-Acute Phase of SARS-CoV-2 Infection in Two Macaque Species Is Associated with Signs of Ongoing Virus Replication and Pathology in Pulmonary and Extrapulmonary Tissues.两种猕猴物种的 SARS-CoV-2 感染后阶段与肺部和肺外组织中持续病毒复制和病理学的迹象有关。
Viruses. 2021 Aug 23;13(8):1673. doi: 10.3390/v13081673.
10
A quantitative model used to compare within-host SARS-CoV-2, MERS-CoV, and SARS-CoV dynamics provides insights into the pathogenesis and treatment of SARS-CoV-2.一种用于比较 SARS-CoV-2、MERS-CoV 和 SARS-CoV 宿主内动力学的定量模型,为 SARS-CoV-2 的发病机制和治疗提供了新的见解。
PLoS Biol. 2021 Mar 22;19(3):e3001128. doi: 10.1371/journal.pbio.3001128. eCollection 2021 Mar.

引用本文的文献

1
Viral Dynamic Models During COVID-19: Are We Ready for the Next Pandemic?新冠疫情期间的病毒动力学模型:我们是否为下一次大流行做好准备?
CPT Pharmacometrics Syst Pharmacol. 2025 Aug;14(8):1289-1297. doi: 10.1002/psp4.70055. Epub 2025 Jun 2.
2
SARS-CoV-2 epidemiology, kinetics, and evolution: A narrative review.严重急性呼吸综合征冠状病毒2型的流行病学、动力学及进化:一篇综述
Virulence. 2025 Dec;16(1):2480633. doi: 10.1080/21505594.2025.2480633. Epub 2025 Apr 8.
3
Translating animal models of SARS-CoV-2 infection to vascular, neurological and gastrointestinal manifestations of COVID-19.

本文引用的文献

1
Success of prophylactic antiviral therapy for SARS-CoV-2: Predicted critical efficacies and impact of different drug-specific mechanisms of action.预防性抗 SARS-CoV-2 病毒治疗的成功:预测的临界疗效和不同药物特异性作用机制的影响。
PLoS Comput Biol. 2021 Mar 1;17(3):e1008752. doi: 10.1371/journal.pcbi.1008752. eCollection 2021 Mar.
2
Modeling SARS-CoV-2 viral kinetics and association with mortality in hospitalized patients from the French COVID cohort.对法国新冠队列中住院患者的严重急性呼吸综合征冠状病毒2(SARS-CoV-2)病毒动力学建模及其与死亡率的关联
Proc Natl Acad Sci U S A. 2021 Feb 23;118(8). doi: 10.1073/pnas.2017962118.
3
将新冠病毒(SARS-CoV-2)感染的动物模型转化为新冠肺炎的血管、神经和胃肠道表现。
Dis Model Mech. 2025 Sep 1;18(9). doi: 10.1242/dmm.052086. Epub 2025 Apr 8.
4
The kinetics of SARS-CoV-2 infection based on a human challenge study.基于人体挑战研究的 SARS-CoV-2 感染动力学。
Proc Natl Acad Sci U S A. 2024 Nov 12;121(46):e2406303121. doi: 10.1073/pnas.2406303121. Epub 2024 Nov 7.
5
Antiviral effect of Evusheld in COVID-19 hospitalized patients infected with pre-Omicron or Omicron variants: a modelling analysis of the randomized DisCoVeRy trial.Evusheld 对感染前奥密克戎或奥密克戎变异株的 COVID-19 住院患者的抗病毒效果:一项随机 DisCoVeRy 试验的建模分析。
J Antimicrob Chemother. 2024 Nov 4;79(11):2887-2895. doi: 10.1093/jac/dkae301.
6
Modeling the emergence of viral resistance for SARS-CoV-2 during treatment with an anti-spike monoclonal antibody.模拟抗刺突单克隆抗体治疗期间 SARS-CoV-2 病毒耐药性的出现。
PLoS Pathog. 2024 Apr 18;20(4):e1011680. doi: 10.1371/journal.ppat.1011680. eCollection 2024 Apr.
7
How robust are estimates of key parameters in standard viral dynamic models?标准病毒动力学模型中关键参数估计的稳健性如何?
PLoS Comput Biol. 2024 Apr 16;20(4):e1011437. doi: 10.1371/journal.pcbi.1011437. eCollection 2024 Apr.
8
Heterogeneous SARS-CoV-2 kinetics due to variable timing and intensity of immune responses.由于免疫反应的时间和强度不同,导致 SARS-CoV-2 的异质性动力学。
JCI Insight. 2024 Apr 4;9(9):e176286. doi: 10.1172/jci.insight.176286.
9
Within-host evolution of SARS-CoV-2: how often are mutations transmitted from symptomatic infections?严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的宿主内进化:有症状感染中产生的突变传播频率如何?
Virus Evol. 2024 Feb 21;10(1):veae006. doi: 10.1093/ve/veae006. eCollection 2024.
10
Modeling the emergence of viral resistance for SARS-CoV-2 during treatment with an anti-spike monoclonal antibody.用抗刺突单克隆抗体治疗期间对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)病毒耐药性出现的建模。
bioRxiv. 2023 Sep 17:2023.09.14.557679. doi: 10.1101/2023.09.14.557679.
Do not neglect SARS-CoV-2 hospitalization and fatality risks in the middle-aged adult population.
不要忽视中年人群中感染新冠病毒后的住院和死亡风险。
Infect Dis Now. 2021 Jun;51(4):380-382. doi: 10.1016/j.idnow.2020.12.007. Epub 2021 Jan 18.
4
REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters.RECON-COV2 抗体可预防和治疗恒河猴和仓鼠感染 SARS-CoV-2。
Science. 2020 Nov 27;370(6520):1110-1115. doi: 10.1126/science.abe2402. Epub 2020 Oct 9.
5
Heterogeneous expression of the SARS-Coronavirus-2 receptor ACE2 in the human respiratory tract.人类呼吸道中 SARS-CoV-2 受体 ACE2 的异质性表达。
EBioMedicine. 2020 Oct;60:102976. doi: 10.1016/j.ebiom.2020.102976. Epub 2020 Sep 21.
6
Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates.羟氯喹在非人类灵长类动物中对抗 SARS-CoV-2 感染的应用。
Nature. 2020 Sep;585(7826):584-587. doi: 10.1038/s41586-020-2558-4. Epub 2020 Jul 22.
7
Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections.无症状 SARS-CoV-2 感染的临床和免疫学评估。
Nat Med. 2020 Aug;26(8):1200-1204. doi: 10.1038/s41591-020-0965-6. Epub 2020 Jun 18.
8
Natural History of Asymptomatic SARS-CoV-2 Infection.无症状SARS-CoV-2感染的自然史。
N Engl J Med. 2020 Aug 27;383(9):885-886. doi: 10.1056/NEJMc2013020. Epub 2020 Jun 12.
9
SARS-CoV-2 infection protects against rechallenge in rhesus macaques.SARS-CoV-2 感染可使恒河猴免受再次感染。
Science. 2020 Aug 14;369(6505):812-817. doi: 10.1126/science.abc4776. Epub 2020 May 20.
10
Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study.2020 年 1 月至 3 月在中国浙江省感染 SARS-CoV-2 的患者的病毒载量动态和疾病严重程度:回顾性队列研究。
BMJ. 2020 Apr 21;369:m1443. doi: 10.1136/bmj.m1443.